Trials / Completed
CompletedNCT00378521
Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon
Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- MediQuest Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
The Purpose of this study is to determine the response to two different strengths of a topical gel containing nitroglycerin in patients with Raynaud's disease.
Detailed description
The Purpose of this clinical study is to determine, in a controlled fashion, the response to two dosage strengths of a topical gel formulation of Nitroglycerin, MQX-503, in the determination of changes in finger blood flow and skin temperature in the fingers of patients with moderate to severe primary Raynaud's phenomenon and with Raynaud's phenomenon secondary to autoimmune diseases, such as scleroderma. The dosage strength response in the treatment of the symptoms (pain, tingling, numbness) will also be monitored.
Conditions
- Raynaud's Disease
- Raynaud's Disease Secondary to Scleroderma
- Raynaud's Disease Secondary to Autoimmune Disease
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MQX-503 |
Timeline
- Start date
- 2006-07-01
- Completion
- 2006-07-01
- First posted
- 2006-09-20
- Last updated
- 2007-05-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00378521. Inclusion in this directory is not an endorsement.